Preclinical monitoring of drug association in experimental chemotherapy of Chagas' disease by a new HPLC-UV method

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3344-3348

  Da Silva, Rodrigo Moreira ^a   Oliveira, Líliam Teixeira ^a   Barcellos, Neila Márcia Silva ^a   De Souza, Jacqueline ^a   De Lana, Marta ^a  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; ITRACONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APPARATUS; AREA UNDER THE CURVE; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENTIATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY ULTRAVIOLET METHOD; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DETECTOR; SINGLE DRUG DOSE; TRYPANOSOMA CRUZI;

ANIMALS; CHAGAS DISEASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; ITRACONAZOLE; MICE; NITROIMIDAZOLES; TRYPANOCIDAL AGENTS;

EID: 84861116188     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05785-11     Document Type: Article

References (31)

1. Abdou HM. 1995. Dissolution, p 593-604. In Mischer A (ed), Remington: the science and practice of pharmacy, 19th ed. Mack Publishing Company Press, Easton, PA.
2. Abou-Audaa HS, Mustafa AA, Al-Humayyd MS. 2008. Pharmacokinetic interaction of ketoconazole and itraconazole with ciprofloxacin. Biopharm. Drug Dispos. 29:29-35. (Pubitemid 351265896)
3. Araújo MS, Martins-Filho OA, Pereira ME, Brener Z. 2000. A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease. J. Antimicrob. Chemother. 45:819-824. (Pubitemid 30348953)
4. Auletta CS. 1995. Acute subchronic and chronic toxicology, p 51-103. In Derelanko MJ Hollinger MA (ed), Handbook of toxicology. CRC Press, Boca Raton, FL.
5. Castro JA, de Mecca MM, Bartel LC. 2006. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum. Exp. Toxicol. 25:471-479. (Pubitemid 44384589)
6. Coura JR. 2009. Present situation and new strategies for Chagas Disease chemotherapy-a proposal. Mem. Inst. Oswaldo Cruz 104:549-554.
7. de Lana M, Chiari E, Tafuri WL. 1992. Experimental Chagas' disease in dogs. Mem. Inst. Oswaldo Cruz. 87:59-71.
8. Dvorak Z. 2011. Drug-drug interactions by azole antifungals: beyond a dogma of CYP3A4 enzyme activity inhibition. Toxicol. Lett. 202:129-132.
9. Edwards G, Krishna S. 2004. Pharmacokinetic and pharmacodynamic issues in the treatment of parasitc infections. Eur. J. Clin. Microbiol. Infect. Dis. 23:233-242. (Pubitemid 38669935)
10. Food and Drug Administration. 2001. Guidance for industry. Bioanalytical method validation. U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Center for Veterinary Medicine, Rockville, MD. http://www.fda.gov/downloads/Drugd/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
11. Garibaldi M, Nagashima R, Levy G. 1969. Relationship between drug concentration in plasma or serum and amount of drug in the body. J. Pharm. Sci. 58:193-197.
12. Guedes PM, et al. 2002. The dog as model for chemotherapy of the Chagas' disease. Acta Trop. 84:9-17. (Pubitemid 35223290)
13. Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE. 2004. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab. Dispos. 32:1121-1131.
14. Janssen-Ortho, Inc. 2011. Sporanox. Product monograph of Janssen-Ortho, Inc., Toronto, Ontario. www.janssen.ca/product/188.
15. Kasim NA, et al. 2004. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharm. 1:85-96.
16. Lamas MC, et al. 2006. Development of parenteral formulations and evaluation of the biological activity of the trypanocide drug benznidazole. Int. J. Pharm. 307:239 -243.
17. Maldonado RA, Molina J, Payares G, Urbina JA. 1993. Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease. Antimicrob. Agents Chemother. 37: 1353-1359. (Pubitemid 23166739)
18. Moreira-Silva R, Oliveira TL, Carvalho MG, Souza J, Lana M. 2011.
19. Validation of a new HPLC-UV method for preclinical monitoring of benznidazole- itraconazole drug association. XXIII International Symposium on Pharmaceutical and Biomedical Analysis. João Pessoa, PB, Brazil. http://www.pba2011.com.
20. Peeters J, Neeskens P, Tollenaere JP, Van Remoortere P, Brewster ME. 2002. Characterization of the interaction of 2-hydroxypropyl - cyclodextrin with itraconazole at pH 2, 4 and 7. J. Pharm. Sci. 91:1414-1422.
21. Olkkola KT, Backman JT, Neuvonen PJ. 1994. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or intraconazole. Clin. Pharmacol. Ther. 55:481-485. (Pubitemid 24192233)
22. Raaflaub J, Ziegler WH. 1979. Single-dose pharmacokinetics of the the trypanosmicide benznidazole in man. Arzneimittelforschung 29:1611-1614. (Pubitemid 10231718)
23. Raether W, Hanel H. 2003. Nitroheterocyclic drugs with broad spectrum activity. Parasitol. Res. 90(Suppl.):S19 -S39.
24. Urbina JA, et al. 1993. Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob. Agents Chemother. 37:580 -591.
25. Urbina JA. 2001. Specific treatment of Chagas disease: current status and new developments. Curr. Opin. Infect. Dis. 14:733-741. (Pubitemid 33141196)
26. Urbina JA, Docampo R. 2003. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol. 19:495-501. (Pubitemid 37329658)
27. Urbina JA. 2010. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop. 115:55-68.
28. Varhe A, Olkkola KT, Neuvonen PJ. 1994. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or intraconazole. Clin. Pharmacol. Ther. 56:601-607. (Pubitemid 124006567)
29. Workman P, White RAS, Walton MI, Owen LN, Twentyman PR. 1984.
30. Preclinical pharmacokinetics of benznidazole. Br. J. Cancer 50:291-303.
31. World Health Organization. 2010. Neglected tropical diseases. First WHO report on neglected tropical diseases. Working to overcome the global impact of neglected tropical diseases. World Health Organization, Geneva, Switzerland. http://www.who.int/neglected-diseases/2010report/en/.